Home › Funds › CAPSTONE INVESTMENT ADVISORS, LLC › MIRM

CAPSTONE INVESTMENT ADVISORS, LLC position in MIRM

MIRUM PHARMACEUTICALS INC · Health Care

CAPSTONE INVESTMENT ADVISORS, LLC reported holding 18,448,000 shares of MIRM (MIRUM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$68.3M, representing 0.84% of its reported portfolio and ranking #22 among its reported holdings. CAPSTONE INVESTMENT ADVISORS, LLC has disclosed MIRM holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)18.45M sh
Reported value held$68.30M
Portfolio Weight0.84%
First reportedQ3 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How CAPSTONE INVESTMENT ADVISORS, LLC's MIRM position evolved

CAPSTONE INVESTMENT ADVISORS, LLC first disclosed a stake in MIRM in Q3 2025 at 10,004 shares (US$733K). The position peaked in Q1 2026 at 27,000,000 shares, worth US$80.8M. Across 4 filings, CAPSTONE INVESTMENT ADVISORS, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 18,448,000 shares valued at US$68.3M — a reduction of -8,552,000 shares quarter over quarter.. Notable position changes include a 239804% increase in Q4 2025 (shares rose 17% over the following quarter), a 32% trim in Q2 2026 (shares fell 27% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 10.00K $733.39K New
Q4 2025 24.00M $62.03M Add
Q1 2026 27.00M $80.78M Add
Q2 2026 18.45M $68.30M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MIRM and 13F data

MIRM (MIRUM PHARMACEUTICALS INC) is a Health Care company. 61 other funds we track also report a position in MIRM — the largest reported positions include Frazier Life Sciences Management, L.P. (US$899.1M), EVENTIDE ASSET MANAGEMENT, LLC (US$146.2M), TANG CAPITAL MANAGEMENT LLC (US$144.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MIRM

All MIRM fund holders →

FAQ

How long has CAPSTONE INVESTMENT ADVISORS, LLC held MIRM?

CAPSTONE INVESTMENT ADVISORS, LLC has disclosed MIRM holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is CAPSTONE INVESTMENT ADVISORS, LLC's current position in MIRM?

As of Q2 2026, CAPSTONE INVESTMENT ADVISORS, LLC holds 18.45M shares of MIRM (MIRUM PHARMACEUTICALS INC), valued at $68.30M, representing 0.84% of its reported portfolio and ranking #22.

Has CAPSTONE INVESTMENT ADVISORS, LLC been buying or selling MIRM?

In the latest 13F filing (Q2 2026), CAPSTONE INVESTMENT ADVISORS, LLC reduced its position in MIRM. The position peaked in Q1 2026 at 27.00M shares.

Which other funds hold MIRM?

Other major institutional holders of MIRM include Frazier Life Sciences Management, L.P., EVENTIDE ASSET MANAGEMENT, LLC, TANG CAPITAL MANAGEMENT LLC, among 61 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.